Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride

To assess the predictive and prognostic aim of interim and end-treatment F-18-fluorocholine PET/CT (FCH-PET/CT) and Tc-99m-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with Radium 223 dichloride (Ra-223). Prospective and multicentre ChoPET-Rad study including 82 patients with CRPC-BM. Baseline, after 3 (interim) and 6 doses (end-treatment) BS and FCH PET/CT were performed in patients who meet the study criteria. Clinical variables, imaging and clinical progression were obtained and their association with progression free survival (PFS), and overall survival (OS) was studied. Agreement between BS and FCH PET/CT response was assessed using Kappa (K) analysis. Median of PFS and OS was 3 and 16 months, respectively. Agreement between interim BS and FCH PET/CT was weak (K: 0.28; p=0.004). No agreement was observed between end-treatment diagnostic studies. Interim and end-treatment FCH PET/CT were related to PFS (p=0.011 and p<0.001, respectively). Therapeutic failure and interim BS and FCH PET/CT showed association with OS (p<0.001, p=0.037 and p=0.008, respectively). Interim and end-treatment FCH PET/CT were good predictors of biochemical progression in patients treated with Ra-223. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.

Automated summary

The ChoPET-Rad study involving 82 patients with CRPC-BM demonstrated that end-treatment FCH PET/CT was associated with PFS and OS, while interim FCH PET/CT was a good predictor of biochemical progression. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.